Figure 1
From: Cross Reactive Material 197 glycoconjugate vaccines contain privileged conjugation sites
Schematic overview of the three orthogonal approaches employed for the in-depth characterisation of CRM197 conjugated with defined synthetic minimal glycoepitope vaccine candidates.
Step 1: The glycan part is synthesised with a spacer carrying an amine group. Step 2: addition of the linker molecule with two leaving groups (LG). Step 3: addition of the glycan linker construct to the carrier protein and subsequent conjugation to a primary amine (e.g. lysine residue).
